| Bioactivity | Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 µM for VEGFR-1/2/3), PDGFR (Ki= 0.008 µM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo[1]. |
| CAS | 1259519-20-4 |
| Formula | C26H25N5O2 |
| Molar Mass | 439.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hao Z, et al., Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016 Sep 8;9:5495-505. |
Sutetinib
CAS: 1259519-20-4 F: C26H25N5O2 W: 439.51
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.